Technical Analysis for HVO - Hvivo Plc

Grade Last Price % Change Price Change
B 17.10 2.09% 0.35
HVO closed up 2.09 percent on Friday, January 27, 2023, on 1.2 times normal volume. Due to the stock's strong uptrend, it may remain overbought for a while. So, if you're looking for a reason to sell, don't put too much weight on it being overbought.

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Strong Up Up Up

Date Alert Name Type % Chg
Pocket Pivot Bullish Swing Setup 0.00%
Calm After Storm Range Contraction 0.00%
Wide Bands Range Expansion 0.00%
Overbought Stochastic Strength 0.00%
Jack-in-the-Box Bullish Bullish Swing Setup 2.09%
Spinning Top Other 2.09%
Calm After Storm Range Contraction 2.09%
Inside Day Range Contraction 2.09%
Wide Bands Range Expansion 2.09%
Overbought Stochastic Strength 2.09%

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
No Alerts Yet. Alerts will only show here if at least one person is tracking alerts on this stock.

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.


Hvivo Plc Description

hVIVO plc operates as a pharmaceutical service and contract research company. The company is involved in testing vaccines and antivirals using human challenge clinical trials. It provides services to big pharma, biotech, government, and public health organizations. The company has a portfolio of human challenge study models for conditions, such as RSV, flu, human rhinovirus, asthma, malaria, cough, and COPD, as well as developing COVID-19 human challenge study model. In addition, the company is developing a database of infectious disease progression data that include Disease in Motion platform, which comprises unique datasets, such as clinical, immunological, virological, and digital (wearable) biomarkers. The Disease in Motion platform has various potential applications across a range of end users, including big technology, wearables, pharma, and biotech companies. Further, the company provides pre­clinical and early clinical research services; sales and marketing services; and biometry, data management, and statistics to its various European pharmaceutical clients, as well as drug development consultancy and services, including CMC (chemistry, manufacturing, and controls), and PK and medical writing to a range of European clients. The company was formerly known as Open Orphan Plc and changed its name to hVIVO plc in October 2022. hVIVO plc is headquartered in London, the United Kingdom.


Sector: Healthcare
Industry: Biotechnology
Keywords: Manufacturing Disease Data Management Biomarker Drug Development Infectious Disease Asthma Cell Biology Copd Malaria

Is HVO a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 21.0
52 Week Low 8.675
Average Volume 2,291,278
200-Day Moving Average 11.97
50-Day Moving Average 12.47
20-Day Moving Average 13.62
10-Day Moving Average 15.71
Average True Range 1.20
RSI 70.76
ADX 39.43
+DI 28.78
-DI 12.34
Chandelier Exit (Long, 3 ATRs) 14.09
Chandelier Exit (Short, 3 ATRs) 13.23
Upper Bollinger Bands 18.50
Lower Bollinger Band 8.75
Percent B (%b) 0.86
BandWidth 71.55
MACD Line 1.36
MACD Signal Line 1.03
MACD Histogram 0.3234
Fundamentals Value
Market Cap 114.47 Million
Num Shares 669 Million
Price-to-Sales 12.40
Price-to-Book 9.22
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 19.95
Resistance 3 (R3) 19.73 18.57 19.47
Resistance 2 (R2) 18.57 17.84 18.67 19.32
Resistance 1 (R1) 17.83 17.39 18.20 18.05 19.16
Pivot Point 16.67 16.67 16.85 16.78 16.67
Support 1 (S1) 15.93 15.94 16.30 16.15 15.04
Support 2 (S2) 14.77 15.49 14.88 14.88
Support 3 (S3) 14.04 14.77 14.73
Support 4 (S4) 14.25